'Cisplatin' diaporamas de présentation

Emerging Treatment Paradigms in NSCLC

Emerging Treatment Paradigms in NSCLC. Edward S. Kim, MD MD Anderson Cancer Center. Per capita cigarette consumption. Male lung cancer death rate. Female lung cancer death rate. Tobacco Use in the USA 1900-1999. *Age-adjusted to 2000 US standard population.

970 views • 73 slides

Non-surgical Treatment of Diffuse Malignant M esothelioma

Non-surgical Treatment of Diffuse Malignant M esothelioma. G u nt u l u Ak , MD Eski s ehir Osmangazi University Medical Faculty Department of Pulmonary Medicine. Conflict of interest statement. None. Contents. Chemotherapy First-line chemotherapy Second-line chemotherapy

653 views • 50 slides

Presenter : Dr.B.Sathish , JR, RT

561 views • 43 slides

Nutritional Supplements That Support Cancer Chemotherapy

Nutritional Supplements That Support Cancer Chemotherapy. Leo Galland, M.D., F.A.C.P. Foundation for Integrated Medicine. General Overview. About 1000 drugs and fixed-drug combinations used in the U.S.: Almost 400 may deplete specific nutrients.

393 views • 38 slides

Ch 22 complex ions

Ch 22 complex ions. Coordination complex is the product of a Lewis acid-base reaction in which neutral molecules or anions (called ligands ) bond to a central metal atom (or ion) by coordinate covalent bonds .

1.47k views • 31 slides

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer. ????? ???? R2 ???. BACKGROUND. Ovarian cancer - leading cause of the death in USA Standard chemotherapy for the initial Tx - combination of a platinum analogue with paclitaxel - with modern surgical intervention

569 views • 29 slides

OPTION MEDICINES and DRUGS and short overview of the option

OPTION MEDICINES and DRUGS and short overview of the option. Outline of this option. Pharmaceutical products Antacids Analgesics Depressants Stimulants Antibacterials Antivirals Drug action (HL) Drug design (HL) Mind altering drugs (HL). What is a medicine or drug?.

404 views • 22 slides

??????

??????. Date: Sep. 11, 2006. 1. ????????,?????????(????),???????? ??????( combined chemotherapy), ????,??,??,???. cyclophosphamide ( 750 mg/m 2 )+ cisplatin( 75 mg/m 2 ) (or carboplatin) q3w x 6 courses

375 views • 22 slides

??????

??????. Date: Sep. 11, 2006. 1. ????????,?????????(????),???????? ??????( combined chemotherapy), ????,??,??,???. cyclophosphamide ( 750 mg/m 2 )+ cisplatin( 75 mg/m 2 ) (or carboplatin) q3w x 6 courses

222 views • 22 slides

Better Regimens & Predictive Markers For Advanced Esophagogastric Cancer?

294 views • 21 slides

Empirical and Molecular Formulas

440 views • 12 slides

Exfoliative Dermatitis

Exfoliative Dermatitis. Miss Wichuta Thawinwan 483150042-1 Miss Saleela Benjawilaikul 483150187-5 Khon Kaen University. Exfoliative Dermatitis ( erythroderma ). Uncommon skin disorder One of the most severe patterns of cutaneous reaction

2.1k views • 10 slides

ASCO/FDA Workshop on Lung Cancer Endpoints Alexandria, VA April 15, 2003

ASCO/FDA Workshop on Lung Cancer Endpoints Alexandria, VA April 15, 2003. Renzo Canetta, M.D. Vice President Life Cycle Management and Clinical Design & Evaluation Oncology Bristol-Myers Squibb Pharmaceutical Research Institute Wallingford, CT, USA. US Europe Japan .

198 views • 10 slides

DNA damage response reaction

DNA damage response reaction. Annu . Rev. Biochem . 2004. 73:39-85 . DNA Base damages. Cisplatin , mitomycin C, psoralen , nitrogen mustard, and adriamycin. Annu . Rev. Biochem . 2004. 73 :39-85 . DNA Backbone damages. Cisplatin , mitomycin D,

228 views • 9 slides

Cisplatin 40 years of platinum based cancer drug

Cisplatin is used as an anti-cancer chemotherapy drug. You can buy highly pureu00a0reference standards of Cisplatin and its impuritiesu00a0fromu00a0Pharmaffiliates Analytics and Synthetics Pvt. Ltdu00a0

142 views • 8 slides

Mesoporous Silica Nanospheres as MRI Contrast Agents

Mesoporous Silica Nanospheres as MRI Contrast Agents. J. Am. Chem. Soc . 2008 , 130 , 2154-2155. a). b). c). d). e). f). Post-Synthetic Modifications of MIL-101 Nanoparticles for Targeted Delivery of Cisplatin and Optical Contrast Agents.

369 views • 3 slides

Suppl. fig. 6

Suppl. fig. 6. A. vehicle. cisplatin. p53. p53. B. C. DAPI. DAPI.

83 views • 1 slides